Perseus Proteomics (TYO:4882) and UBE have entered a collaborative research agreement focused on antibody-drug conjugates (ADC), which are used to kill cancer cells, according to its filing on Monday.
The partnership will enhance the development of PPMX-T004, an ADC, and explore additional ADCs using external drug discovery sources.
Their combined technologies will optimize antibody and drug/linker combinations for effective treatments.
Price (JPY): $610.00, Change: $+2.0, Percent Change: +0.33%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。